You are here

ANALYSIS OF NA2B12H11SH FOR NEUTRON CAPTURE THERAPY

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 7159
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1987
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
900 Altantic Drive Northwest
Atlanta, GA 30318
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JACALYN M SCHREMMER
 (404) 873-6309
Business Contact
Phone: () -
Research Institution
N/A
Abstract

NUCLEAR MEDICINE, INC. (NMI) INTENDS TO COMMERCIALIZE AN ALTERNATE FORM OF RADIATION THERAPY KNOWN AS BORON NEUTRON CAPTURE THERAPY (BNCT). THIS THERAPY IS CURRENTLY AND SUCCESSFULLY BEING USED IN JAPAN TO TREAT BRAIN TUMORS. THEFOOD AND DRUG ADMINISTRATION REQUIRES CHEMICAL CHARACTERIZATION OF NA2B12H11SH, THE PHARMACEUTICAL THAT MAKES THE THERAPY POSSIBLE, BEFORE IT WILL APPROVE CLINICAL TRIALS FOR BNCT IN THE UNITED STATES. NMI HAS OBTAINED ORPHAN DRUG STATUS FOR NA2B12H11SH AND PROPOSES TWO DIFFERENT QUANTITATIVE METHODS FOR MEASURING ITS PURITY: TRACK-ETCH/THIN-LAYER CHROMATOGRAPHY (TLC) AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC). THE FORMER METHOD ALLOWS THE SENSITIVE MEASUREMENT OF THE (10)B ISOTOPEIN THE BORON POLYHEDRON. MEASUREMENT BY HPLC IS BASED ON ANALYSIS OF THE SULFHYDRYL GROUP ON B12H11SH(2)- BY ELECTRO-CHEMICAL OR OTHER MEANS. THE TECHNIQUES THUS COMPLEMENT ONE ANOTHER AND CAN BE SYMBIOTICALLY APPLIED TO BOTH CHEMICAL AND BIOCHEMICAL ANALYSIS OF BORON-CARRIER COMPOUNDS.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government